ANCA Associated Vasculitis - Epidemiology Forecast

List of Tables

ANCA Vasculitis Insights and Trends

According to DelveInsight's estimates, in 2025, there were nearly ~226,000 diagnosed prevalent cases of ANCA Vasculitis in the 7MM.
ANCA Vasculitis predominantly affects older adults, with peak onset typically occurring between the sixth and eighth decades of life, though cases can occur at any age. Many cohorts show a slight male predominance, but sex differences are modest and vary by region and subtype.
As per Bataille et al. (2022), in people over 20 years of age, age-standardized prevalence rates for granulomatosis with polyangiitis (GPA) were 10 per 100,000 person-years, respectively.
As per Hellmich et al. (2021), the prevalence of GPA is 210 cases per million people. Hence, 17,500 ANCA Vasculitis patients (GPA and MPA) are estimated to live in Germany, with an annual increase of 3,200 patients.
As per Hwee et al. (2022), the prevalence of EGPA increased from 22.7 to 45.6 per 1,000,000 persons from 2005 to 2019 in the UK.
As per Moura et al. (2022), particularly in GPA, ANCA Vasculitis affects 87%, 78%, 61.5%, 42.5%, 30%, 17.5%, 10%, and 3.5% in the upper respiratory tract, lower respiratory tract, renal impairment, eye involvement, cutaneous manifestation, nervous system, cardiovascular, and gastrointestinal, respectively.
Additionally, the prevalence of these conditions is geographically heterogeneous; GPA is more prevalent in European countries, while in Asian countries (especially Japan), microscopic polyangiitis (MPA) is more prevalent.

DelveInsight's 'ANCA Vasculitis - Epidemiology Forecast - 2036' report delivers an in-depth understanding of the ANCA Vasculitis, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

ANCA Vasculitis Understanding and Diagnosis Algorithm

ANCA Vasculitis Overview

ANCA vasculitis is a rare, life-threatening autoimmune disease characterized by inflammation and destruction of small blood vessels, which can lead to significant organ damage. The disease primarily affects the kidneys, lungs, upper respiratory tract, skin, nerves, and other organs. ANCA vasculitis is broadly classified into three major subtypes: GPA, MPA, and eosinophilic granulomatosis with polyangiitis (EGPA), each differing in clinical presentation and organ involvement. The disease occurs when the immune system mistakenly attacks healthy blood vessels, leading to inflammation, reduced blood flow, and tissue damage. If left untreated, ANCA vasculitis can result in severe complications such as kidney failure, pulmonary hemorrhage, and permanent organ dysfunction.

ANCA Vasculitis Diagnosis

The diagnosis of ANCA vasculitis involves a combination of clinical evaluation, laboratory testing, imaging studies, and tissue biopsy to confirm disease subtype and assess organ involvement. Blood tests are commonly used to detect anti-neutrophil cytoplasmic antibodies (ANCA), including proteinase-3 (PR3-ANCA) and myeloperoxidase (MPO-ANCA), which are key diagnostic markers. Additional laboratory tests may include inflammatory markers, kidney function tests, and urinalysis to evaluate disease severity. Imaging techniques such as CT scans, chest X-rays, and MRI may help identify lung or sinus involvement. In many cases, a tissue biopsy of the kidney, lung, skin, or other affected organs remains the gold standard for confirming vasculitis and determining the extent of vascular inflammation. Early diagnosis is critical to initiating timely treatment and preventing irreversible organ damage.

ANCA Vasculitis Epidemiology

Key Findings from ANCA Vasculitis Epidemiological Analysis and Forecast

According to DelveInsight's estimates, there were approximately 226,000 diagnosed prevalent cases of ANCA vasculitis across the 7MM in 2025, with the United States accounting for the highest share.
Among EU4, Germany accounted for the largest number of diagnosed prevalent cases of ANCA Vasculitis, followed by Italy, whereas Spain accounted for the lowest cases in 2025.
In 2025, pANCAs/MPO-ANCAs represented the most commonly diagnosed antibody-specific subtype of AAV in MPA, accounting for approximately 28,000 cases in the US.
In 2025, the diagnosed prevalent cases of MPA by organ involvement in the UK were highest in renal impairment, followed by other organs such as the lower respiratory tract, cutaneous manifestations, gastrointestinal involvement, nervous system, upper respiratory tract, cardiovascular involvement, and eye involvement.
Granulomatosis with polyangiitis was found to be more prevalent than any other type of ANCA Vasculitis in the United States (~35,000).

Scope of the Report:

The report covers a segment of an executive summary, a descriptive overview of ANCA Vasculitis, explaining its causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

ANCA Vasculitis Patient Population Forecast

Report Key Strengths

Epidemiology-based (epi-based) Bottom-up Forecasting
11-year Forecast
Patient Burden Trends (by geography)

FAQs:

What are the disease risks, burdens, and unmet needs of ANCA Vasculitis? What will be the growth opportunities across the 7MM concerning the patient population with ANCA Vasculitis?
What is the historical and forecasted ANCA Vasculitis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy:

Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders' perspectives on the diagnostic challenges to overcome barriers in the future.
Detailed insights into various factors hampering disease diagnosis and other existing diagnostic challenges.

Product Code: DIEI1766

1. Key Insights

2. Report Introduction

3. Executive Summary of ANCA Vasculitis

4. Epidemiology Forecast Methodology of ANCA Vasculitis

5. ANCA Vasculitis Epidemiology Overview at a Glance

5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM

6. ANCA Vasculitis Disease Background and Overview

6.1. Introduction
6.2. Symptom
6.3. Transmission and Risk Factors
6.4. Pathophysiology
6.5. Diagnosis and Screening
- 6.5.1. Diagnostic Algorithm
- 6.5.2. Diagnosis Guidelines

7. ANCA Vasculitis Epidemiology and Patient Population

7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Diagnosed Prevalent Cases of ANCA Vasculitis in the 7MM
7.4. The United States
- 7.4.1. Total Diagnosed Prevalent Cases of ANCA Vasculitis in the United States
- 7.4.2. Type-specific Diagnosed Prevalent Cases of ANCA Vasculitis in the United States
- 7.4.3. Severity-specific Diagnosed Prevalence of ANCA Vasculitis in the United States
- 7.4.4. Diagnosed Prevalent Cases of ANCA Vasculitis by Organ Involvement in the United States
- 7.4.5. Diagnosed Prevalent Cases of ANCA Vasculitis by Antibody Type in the United States
- 7.4.6. Total Treated Cases of ANCA Vasculitis by Type in the United States
7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Prevalent Cases of ANCA Vasculitis in EU4 and the UK
- 7.5.2. Type-specific Diagnosed Prevalent Cases of ANCA Vasculitis in EU4 and the UK
- 7.5.3. Severity-specific Diagnosed Prevalence of ANCA Vasculitis in EU4 and the UK
- 7.5.4. Diagnosed Prevalent Cases of ANCA Vasculitis by Organ Involvement in EU4 and the UK
- 7.5.5. Diagnosed Prevalent Cases of ANCA Vasculitis by Antibody Type in EU4 and the UK
- 7.5.6. Total Treated Cases of ANCA Vasculitis by Type in EU4 and the UK
7.6. Japan
- 7.6.1. Total Diagnosed Prevalent Cases of ANCA Vasculitis in Japan
- 7.6.2. Type-specific Diagnosed Prevalent Cases of ANCA Vasculitis in Japan
- 7.6.3. Severity-specific Diagnosed Prevalence of ANCA Vasculitis in Japan
- 7.6.4. Diagnosed Prevalent Cases of ANCA Vasculitis by Organ Involvement in Japan
- 7.6.5. Diagnosed Prevalent Cases of ANCA Vasculitis by Antibody Type in Japan
- 7.6.6. Total Treated Cases of ANCA Vasculitis by Type in Japan

8. Appendix

8.1. Bibliography
8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Product Code: DIEI1766

List of Tables

Table 1: Summary of ANCA Associated Vasculitis, Epidemiology, and Key Events (2022-2036)
Table 2: ANCA Associated Vasculitis Symptoms
Table 3: Core Clinical Features of MPA, GPA, and EGPA
Table 4: Major Inflammatory Substances in ANCA-associated Vasculitis
Table 5: Factors Influencing Autoimmune Activation of Neutrophils by PR3-ANCA
Table 6: Classification Criteria for GPA
Table 7: Classification Criteria for EGPA
Table 8: Classification Criteria for MPA
Table 9: Differences Between PR3 ANCA Vasculitis and MPO-ANCA Vasculitis
Table 10: When to consider ANCA-associated Vasculitis
Table 11: Differential Diagnosis of GPA
Table 12: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in the 7MM and China (2022-2036)
Table 13: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in the US (2022-2036)
Table 14: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in the US (2022-2036)
Table 15: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Organ Involvement in the US (2022-2036)
Table 16: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Antibody Type in the US (2022-2036)
Table 17: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Severity in the US (2022-2036)
Table 18: Total Treated Cases of ANCA Associated Vasculitis by Type in the US (2022-2036)
Table 19: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in EU4 and the UK (2022-2036)
Table 20: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in EU4 and the UK (2022-2036)
Table 21: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Organ Involvement in EU4 and the UK (2022-2036)
Table 22: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Antibody Type in EU4 and the UK (2022-2036)
Table 23: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Severity in EU4 and the UK (2022-2036)
Table 24: Total Treated Cases of ANCA Associated Vasculitis by Type in EU4 and the UK (2022-2036)
Table 25: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in Japan (2022-2036)
Table 26: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in Japan (2022-2036)
Table 27: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Organ Involvement in Japan (2022-2036)
Table 28: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Antibody Type in Japan (2022-2036)
Table 29: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Severity in Japan (2022-2036)
Table 30: Total Treated Cases of ANCA Associated Vasculitis by Type in Japan (2022-2036)
Table 31: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in China (2022-2036)
Table 32: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in China (2022-2036)
Table 33: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Organ Involvement in China (2022-2036)
Table 34: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Antibody Type in China (2022-2036)
Table 35: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Severity in China (2022-2036)
Table 36: Total Treated Cases of ANCA Associated Vasculitis by Type in China (2022-2036)

List of Figures

Figure 1: Epidemiology Methodology
Figure 2: Clinical Features of ANCA Associated Vasculitis
Figure 3: Clinical Manifestations of EGPA
Figure 4: Ear, Nose, and Throat Features in GPA According to the Anatomical Region Involvement
Figure 5: Approach Toward Pathogenesis of ANCA Associated Vasculitis
Figure 6: Factors Associated With EGPA Pathogenesis
Figure 7: Pathogenic Model Highlighting the Differences Between PR3-ANCA and MPO- ANCA
Figure 8: Differences Between PR3 and MPO and Their Respective ANCAs
Figure 9: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in the 7MM and China (2022-2036)
Figure 10: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in the US (2022-2036)
Figure 11: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in the US (2022-2036)
Figure 12: Diagnosed Prevalent Cases of MPA by Organ Involvement in the US (2022-2036)
Figure 13: Diagnosed Prevalent Cases of GPA by Organ Involvement in the US (2022-2036)
Figure 14: Diagnosed Prevalent Cases of EGPA by Organ Involvement in the US (2022-2036)
Figure 15: Diagnosed Prevalent Cases of MPA by Antibody Type in the US (2022-2036)
Figure 16: Diagnosed Prevalent Cases of GPA by Antibody Type in the US (2022-2036)
Figure 17: Diagnosed Prevalent Cases of EGPA by Antibody Type in the US (2022-2036)
Figure 18: Diagnosed Prevalent Cases of MPA by Severity in the US (2022-2036)
Figure 19: Diagnosed Prevalent Cases of GPA by Severity in the US (2022-2036)
Figure 20: Diagnosed Prevalent Cases of EGPA by Severity in the US (2022-2036)
Figure 21: Total Treated Cases of MPA in the US (2022-2036)
Figure 22: Total Treated Cases of GPA in the US (2022-2036)
Figure 23: Total Treated Cases of EGPA in the US (2022-2036)
Figure 24: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in EU4 and the UK (2022-2036)
Figure 25: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in EU4 and the UK (2022-2036)
Figure 26: Diagnosed Prevalent Cases of MPA by Organ Involvement in EU4 and the UK (2022-2036)
Figure 27: Diagnosed Prevalent Cases of GPA by Organ Involvement in EU4 and the UK (2022-2036)
Figure 28: Diagnosed Prevalent Cases of EGPA by Organ Involvement in EU4 and the UK (2022-2036)
Figure 29: Diagnosed Prevalent Cases of MPA by Antibody Type in EU4 and the UK (2022-2036)
Figure 30: Diagnosed Prevalent Cases of GPA by Antibody Type in EU4 and the UK (2022-2036)
Figure 31: Diagnosed Prevalent Cases of EGPA by Antibody Type in EU4 and the UK (2022-2036)
Figure 32: Diagnosed Prevalent Cases of MPA by Severity in EU4 and the UK (2022-2036)
Figure 33: Diagnosed Prevalent Cases of GPA by Severity in EU4 and the UK (2022-2036)
Figure 34: Diagnosed Prevalent Cases of EGPA by Severity in EU4 and the UK (2022-2036)
Figure 35: Total Treated Cases of MPA in EU4 and the UK (2022-2036)
Figure 36: Total Treated Cases of GPA in EU4 and the UK (2022-2036)
Figure 37: Total Treated Cases of EGPA in EU4 and the UK (2022-2036)
Figure 38: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in Japan (2022-2036)
Figure 39: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in Japan (2022-2036)
Figure 40: Diagnosed Prevalent Cases of MPA by Organ Involvement in Japan (2022-2036)
Figure 41: Diagnosed Prevalent Cases of GPA by Organ Involvement in Japan (2022-2036)
Figure 42: Diagnosed Prevalent Cases of EGPA by Organ Involvement in Japan (2022-2036)
Figure 43: Diagnosed Prevalent Cases of MPA by Antibody Type in Japan (2022-2036)
Figure 44: Diagnosed Prevalent Cases of GPA by Antibody Type in Japan (2022-2036)
Figure 45: Diagnosed Prevalent Cases of EGPA by Antibody Type in Japan (2022-2036)
Figure 46: Diagnosed Prevalent Cases of MPA by Severity in Japan (2022-2036)
Figure 47: Diagnosed Prevalent Cases of GPA by Severity in Japan (2022-2036)
Figure 48: Diagnosed Prevalent Cases of EGPA by Severity in Japan (2022-2036)
Figure 49: Total Treated Cases of MPA in Japan (2022-2036)
Figure 50: Total Treated Cases of GPA in Japan (2022-2036)
Figure 51: Total Treated Cases of EGPA in Japan (2022-2036)
Figure 52: Total Diagnosed Prevalent Cases of ANCA Associated Vasculitis in China (2022-2036)
Figure 53: Diagnosed Prevalent Cases of ANCA Associated Vasculitis by Type in China (2022-2036)
Figure 54: Diagnosed Prevalent Cases of MPA by Organ Involvement in China (2022-2036)
Figure 55: Diagnosed Prevalent Cases of GPA by Organ Involvement in China (2022-2036)
Figure 56: Diagnosed Prevalent Cases of EGPA by Organ Involvement in China (2022-2036)
Figure 57: Diagnosed Prevalent Cases of MPA by Antibody Type in China (2022-2036)
Figure 58: Diagnosed Prevalent Cases of GPA by Antibody Type in China (2022-2036)
Figure 59: Diagnosed Prevalent Cases of EGPA by Antibody Type in China (2022-2036)
Figure 60: Diagnosed Prevalent Cases of MPA by Severity in China (2022-2036)
Figure 61: Diagnosed Prevalent Cases of GPA by Severity in China (2022-2036)
Figure 62: Diagnosed Prevalent Cases of EGPA by Severity in China (2022-2036)
Figure 63: Total Treated Cases of MPA in China (2022-2036)
Figure 64: Total Treated Cases of GPA in China (2022-2036)
Figure 65: Total Treated Cases of EGPA in China (2022-2036)

ANCA Associated Vasculitis - Epidemiology Forecast - 2036

Description

Table of Contents

List of Tables

ANCA Vasculitis Insights and Trends

ANCA Vasculitis Epidemiology

Scope of the Report:

Report Insights

Report Key Strengths

FAQs:

Reasons to Buy:

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of ANCA Vasculitis

4. Epidemiology Forecast Methodology of ANCA Vasculitis

5. ANCA Vasculitis Epidemiology Overview at a Glance

6. ANCA Vasculitis Disease Background and Overview

7. ANCA Vasculitis Epidemiology and Patient Population

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

List of Tables

List of Figures